Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Shukui Qin(81th Hospital of PLA), Chunyi Hao(Peking University), Gwo Fuang Ho(University of Malaya), Yu Zhou(Ningbo University), Yimin Mao(Beijing Hospital), Zhenggang Ren(Ministry of Education of the People's Republic of China), Wenyan Zhong(Huazhong Agricultural University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Baek‐Yeol Ryoo(Asan Medical Center), Yuxian Bai(Harbin Medical University), Jianfeng Li(First Hospital of China Medical University), Xiufeng Liu(Sichuan University), Zhendong Chen(Anhui Medical University), Juxiang Xiao(First Affiliated Hospital of Xi'an Jiaotong University), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ruocai Xu(Hunan Cancer Hospital), Zhiqiang Meng(Fudan University Shanghai Cancer Center), Xin Wang(Hong Kong University of Science and Technology), Weijia Fang(Zhejiang Cancer Hospital)
Cited by 191
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k